Ryoichi Shimomura
Fujita Health University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ryoichi Shimomura.
Clinical Cancer Research | 2009
Nobutake Yamamichi; Ryoichi Shimomura; Ken-ichi Inada; Kouhei Sakurai; Takeshi Haraguchi; Yuka Ozaki; Shuji Fujita; Taketoshi Mizutani; Chihiro Furukawa; Mitsuhiro Fujishiro; Masao Ichinose; Kazuya Shiogama; Yutaka Tsutsumi; Masao Omata; Hideo Iba
Purpose: To better understand microRNA miR-21 function in carcinogenesis, we analyzed miR-21 expression patterns in different stages of colorectal cancer development using in situ hybridization (ISH). Experimental Design: Locked nucleic acid (LNA)/DNA probes and a biotin-free tyramide signal amplification system were used in ISH analyses of miRNA expression. Conditions for specific detection of miR-21 were determined using human cell lines and miR-21–expressing lentiviral vectors. Expression was determined in 39 surgically excised colorectal tumors and 34 endoscopically resected colorectal polyps. Results: In the surgical samples, miR-21 expression was much higher in colorectal cancers than in normal mucosa. Strong miR-21 expression was also observed in cancer-associated stromal fibroblasts, suggesting miR-21 induction by cancer-secreted cytokines. Protein expression of PDCD4, a miR-21 target, was inversely correlated with miR-21 expression, confirming that miR-21 is indeed a negative regulator of PDCD4 in vivo. In the endoscopic samples, miR-21 expression was very high in malignant adenocarcinomas but was not elevated in nontumorigenic polyps. Precancerous adenomas also frequently showed miR-21 up-regulation. Conclusion: Using the LNA-ISH system for miRNA detection, miR-21 was detectable in precancerous adenomas. The frequency and extent of miR-21 expression increased during the transition from precancerous colorectal adenoma to advanced carcinoma. Expression patterns of miR-21 RNA and its target, tumor suppressor protein PDCD4, were mutually exclusive. This pattern may have clinical application as a biomarker for colorectal cancer development and might be emphasized by self-reinforcing regulatory systems integrated with the miR-21 gene, which has been previously shown in cell culture.
Experimental Cell Research | 2009
Nobutake Yamamichi; Ken-ichi Inada; Chihiro Furukawa; Kouhei Sakurai; Toshio Tando; Aya Ishizaka; Takeshi Haraguchi; Taketoshi Mizutani; Mitsuhiro Fujishiro; Ryoichi Shimomura; Masashi Oka; Masao Ichinose; Yutaka Tsutsumi; Masao Omata; Hideo Iba
In our recent study showing a correlation between Brm-deficiency and undifferentiated status of gastric cancer, we found that the Brm-type SWI/SNF complex is required for villin expression. To elucidate intestinal villin regulation more precisely, we here analyzed structure and function of the promoter of human villin. About 1.1 kb upstream of the determined major transcription start site, we identified a highly conserved region (HCR-Cdx) among mammals, which contains two binding sites for Cdx. Expression analyses of 30 human gastrointestinal cell lines suggested that villin is regulated by Cdx2. Introduction of Cdx family genes into colorectal SW480 cells revealed that villin is strongly induced strongly by Cdx2, moderately by Cdx1, and marginally by Cdx4. Knockdown of Cdx2 in SW480 cells caused a clear downregulation of villin, and reporter assays showed that HCR-Cdx is crucial for Cdx2-dependent and Brm-dependent villin expression. Immunohistochemical analyses of gastric intestinal metaplasia and cancer revealed that villin and Cdx2 expression are tightly coupled. GST pull-down assays demonstrated a direct interaction between Cdx2 and several SWI/SNF subunits. Chromatin immunoprecipitation analyses showed the recruitment of Cdx2 and Brm around HCR-Cdx. From these results, we concluded that Cdx2 regulates intestinal villin expression through recruiting Brm-type SWI/SNF complex to the villin promoter.
British Journal of Cancer | 2007
Shingo Kamoshida; Mai Suzuki; Ryoichi Shimomura; Yoichi Sakurai; Y Komori; I Uyama; Yutaka Tsutsumi
High expression of thymidylate synthase (TS) and inactivation of p53 are allegedly associated with chemoresistance. The authors evaluated TS and p53 expression in gastric cancer treated with neoadjuvant S-1/cisplatin chemotherapy. Paraffin sections of pretreatment biopsy and surgical specimens from 41 gastric cancers were immunostained for TS and p53 protein after appropriate antigen retrieval. Fifty-one cases without neoadjuvant chemotherapy were also studied. In the pretreatment biopsies, high expression of TS was seen in 8% of the histologic responders, in 28% of the nonresponders and in 31% of the controls. High expression of p53 was observed in 56% of the nonresponders, but in 8% of the responders and in 29% of the controls (P<0.01 and P<0.05, respectively). The TS- and/or p53-high phenotype was seen in 76% of the nonresponders and in 54% of the controls, but in 8% of the responders (P<0.0001 and P<0.005, respectively). The data of the surgical specimens were consistent with those of the pretreatment biopsies. These results suggest that immunostaining for TS and p53 protein is useful for pretreatment selection of gastric cancer patients unresponsive to S-1/cisplatin chemotherapy.
Pathology International | 2004
Shingo Kamoshida; Hiroshi Matsuoka; Kazuya Shiogama; Atsuji Matsuyama; Ryoichi Shimomura; Ken-ichi Inada; M. Maruta; Yutaka Tsutsumi
High expression of thymidylate synthase (TS) is allegedly associated with the chemoresistance to 5‐fluorouracil (5‐FU) in colorectal cancers. However, low TS expression does not necessarily imply chemosensitivity. Inactivation of p16INK4a correlates with poor prognosis in various cancers. We immunohistochemically evaluated the relationship between the expression of TS, p16INK4a, CDK4 and cyclin D1 and the effect of 5‐FU‐based chemotherapy in colorectal cancers. After antigen retrieval, immunoperoxidase staining was performed on the paraffin‐embedded, biopsy and surgical specimens of 37 advanced colorectal cancers preoperatively treated with peroral administration of 5‐FU derivatives. As a control group, 31 colorectal cancers without preoperative treatment were analyzed. High TS expression was found in 23 (74%) of 31 tumors resected from histological non‐responders and in 19 (61%) of 31 controls but in none of six responders. High p16INK4a expression was seen in 83% of the responders, 52% of the non‐responders and 32% of the controls. The TS‐low/p16INK4a‐high phenotype was noted in 83% of the responders, but only in 3% of the non‐responders (P = 0.0001). Induction of p16INK4a expression after chemotherapy was predominantly seen in the responders. Neither CDK4 nor cyclin D1 expression was related to the chemotherapeutic effects. In conclusion, the combination of low expression of TS and induction of p16INK4a after chemotherapy can be important indicators of the sensitivity to 5‐FU‐based chemotherapy in colorectal cancers.
Journal of Histochemistry and Cytochemistry | 2009
Yasuyoshi Mizutani; Shinya Tsuge; Kazuya Shiogama; Ryoichi Shimomura; Shingo Kamoshida; Ken-ichi Inada; Yutaka Tsutsumi
The enzyme-labeled antigen method is a histochemical technique that visualizes antigen-specific antibody-producing cells in tissue sections, originally documented in 1968. In this study, we attempted to reemerge this hidden but potentially useful method in rat models immunized with horseradish peroxidase (HRP), ovalbumin (OA), or keyhole limpet hemocyanin (KLH). After repeated immunization in footpads, popliteal, groin, and axillary lymph nodes and spleen were sampled. Paraformaldehyde-prefixed frozen sections were incubated with HRP, biotinylated OA, or biotinylated KLH. Proteinase K pretreatment and the secondary use of HPR-labeled streptavidin were applied in the latter two situations. Plasma cells producing antigen-specific antibodies were visualized. Proportions of antigen-specific antibody-producing cells in total plasma cells shown with the immunoperoxidase method for rat immunoglobulins were evaluated. The percentage of antigen-specific plasma cells reached ∼50% of total plasma cells in the regional lymph nodes. The specificity was confirmed by (a) negativity in non-immune rat tissue, (b) negativity with indifferent antigen probes, and (c) abolishment of the reactivity with the corresponding rat serum. In buffered formalin-fixed, paraffin-embedded tissues, fewer plasma cells were labeled for HRP and KLH antibody reactivity after strong proteolysis and prolonged incubation. Expectedly, this method allows us to observe antigen-specific antibody-producing cells under varied pathological conditions.
Journal of Medical Virology | 2010
Kazuya Shiogama; Hidemi Teramoto; Yukiko Morita; Yasuyoshi Mizutani; Ryoichi Shimomura; Ken-ichi Inada; Toshio Kamahora; Masanao Makino; Yutaka Tsutsumi
Oku‐Komyo‐En is one of the national leprosy sanatoria, located on a small island in Setouchi city, Okayama prefecture of Japan since 1938. Since autopsies were carried out routinely on almost all patients who had died in the sanatorium up to 1980, approximately 1,000 formalin‐fixed autopsy tissue samples were available for analysis. When these samples were reviewed, the pathological data indicated a sharp rise in the death rate caused by cirrhosis of the liver and hepatocellular carcinoma (HCC) since 1960 and 1970, respectively. Hepatitis C virus (HCV) infection is a common cause of HCC in Japan. The presence of HCV RNA was demonstrated in paraffin sections prepared from the autopsied liver tissue fixed in formalin for a prolonged period of time, by employing nested RT‐PCR using type‐specific primers. The data showed that HCV RNA was detectable in samples of the liver archived as early as 1940, representing the liver tissues kept in formalin for up to 67 years. HCV genotypes 1b and 2a were found by RT‐PCR at 85.7% and 14.3%, respectively, in patients with leprosy. J. Med. Virol. 82:556–561, 2010.
Oncology Reports | 2005
Shingo Kamoshida; Kazuya Shiogama; Ryoichi Shimomura; Ken-ichi Inada; Yoichi Sakurai; Masahiro Ochiai; Hiroshi Matuoka; Kotaro Maeda; Yutaka Tsutsumi
Japanese Journal of Clinical Oncology | 2004
Shingo Kamoshida; Hiroshi Matsuoka; Taro Ishikawa; Kotaro Maeda; Ryoichi Shimomura; Ken-ichi Inada; Yutaka Tsutsumi
Acta Histochemica Et Cytochemica | 2003
Shingo Kamoshida; Hiroshi Matsuoka; Atsuji Matsuyama; Ryoichi Shimomura; M. Maruta; Yutaka Tsutsumi
Acta Histochemica Et Cytochemica | 2003
Shingo Kamoshida; Kazuya Shiogama; Hiroshi Matsuoka; Atsuji Matsuyama; Ryoichi Shimomura; Ken-ichi Inada; M. Maruta; Yutaka Tsutsumi